Literature DB >> 25582442

Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.

F A Tohme1, R S Kalil, C P Thomas.   

Abstract

BACKGROUND: BK viral nephropathy is an increasingly recognized cause of early allograft loss in kidney transplantation. This study aimed to determine whether a sirolimus (Sir)-based calcineurin inhibitor-sparing regimen is associated with a lower incidence of BK viremia.
METHODS: This was a single-center retrospective study. Patients were either on tacrolimus (Tac)-based or on Sir-based immunosuppression. Conversion from Tac to Sir occurred at or after 3 months if patients were <62 years of age, had calculated panel reactive antibodies of <20%, and did not have acute early rejection.
RESULTS: Incidence of clinically significant BK viremia was 17.9% in the Tac group and 4.3% in the Sir group. Cox regression multivariate analysis showed that male gender (hazard ratio [HR] = 2.87) and switch to Sir (HR = 0.333) impacted the incidence of BK viremia. Kaplan-Meier analysis showed a higher BK-free survival in the Sir group. A trend was seen toward shorter time to resolution of BK viremia and lower peak viremia in the Sir group. Patients on Sir had a higher estimated glomerular filtration rate at each time point; 34% of patients discontinued Sir because of side effects.
CONCLUSION: Conversion to Sir-based maintenance immunosuppression at or about 3 months after kidney transplantation correlates with a lower incidence of BK viremia.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BK virus; calcineurin inhibitor sparing; kidney transplantation; sirolimus; tacrolimus

Mesh:

Substances:

Year:  2015        PMID: 25582442     DOI: 10.1111/tid.12347

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  6 in total

Review 1.  BK polyoma virus infection and renal disease in non-renal solid organ transplantation.

Authors:  Sarat Kuppachi; Deepkamal Kaur; Danniele G Holanda; Christie P Thomas
Journal:  Clin Kidney J       Date:  2015-12-30

Review 2.  Polyoma virus nephropathy in kidney transplantation.

Authors:  Jacob Rw Scadden; Adnan Sharif; Kassi Skordilis; Richard Borrows
Journal:  World J Transplant       Date:  2017-12-24

Review 3.  The Role of HLA and KIR Immunogenetics in BK Virus Infection after Kidney Transplantation.

Authors:  Marija Burek Kamenaric; Vanja Ivkovic; Ivana Kovacevic Vojtusek; Renata Zunec
Journal:  Viruses       Date:  2020-12-09       Impact factor: 5.048

Review 4.  BK Virus Nephropathy in Kidney Transplantation: A State-of-the-Art Review.

Authors:  Sam Kant; Alana Dasgupta; Serena Bagnasco; Daniel C Brennan
Journal:  Viruses       Date:  2022-07-25       Impact factor: 5.818

Review 5.  BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection.

Authors:  Darlene Vigil; Nikifor K Konstantinov; Marc Barry; Antonia M Harford; Karen S Servilla; Young Ho Kim; Yijuan Sun; Kavitha Ganta; Antonios H Tzamaloukas
Journal:  World J Transplant       Date:  2016-09-24

Review 6.  Place of mTOR inhibitors in management of BKV infection after kidney transplantation.

Authors:  Thomas Jouve; Lionel Rostaing; Paolo Malvezzi
Journal:  J Nephropathol       Date:  2015-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.